2019年中国肿瘤流行病学研究进展

陈宏达; 郑荣寿; 王乐; 吕章艳; 杜灵彬; 魏文强; 代敏

doi:10.16462/j.cnki.zhjbkz.2020.04.001

2019年中国肿瘤流行病学研究进展

doi: 10.16462/j.cnki.zhjbkz.2020.04.001

1.
100021 北京, 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院, 癌症早诊早治办公室
2.
100021 北京, 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院, 肿瘤登记办公室
3.
310022 杭州, 中国科学院肿瘤与基础医学研究所/中国科学院大学附属肿瘤医院防治科/浙江省肿瘤医院防治科

基金项目: 国家重点研发计划精准医学专项(2017YFC0907900;2016YFC0901400);中国医学科学院医学与健康科技创新工程(2017-I2M-1-006);国家自然科学基金(81703309);北京市科技新星计划(Z191100001119065)

详细信息

通讯作者:
代敏, E-mail:daimin2002@hotmail.com

中图分类号: R730.1
计量
- 文章访问数: 2557
- HTML全文浏览量: 622
- PDF下载量: 622
- 被引次数: 0
出版历程
- 收稿日期: 2020-03-19
- 修回日期: 2020-04-01
- 刊出日期: 2020-04-10

Progress in cancer epidemiology research in China in 2019

1.
Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2.
Office of Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
3.
Institute of Cancer and Basic Medicine (ICBM),Chinese Academy of Sciences/Department of Cancer Prevention,Cancer Hospital of the University of Chinese Academy of Sciences/Department of Cancer Prevention,Zhejiang Cancer Hospital,Hangzhou 310022,China

Funds: National Key Research and Development Project-Precision Medicine(2017YFC0907900, 2016YFC0901400); CAMS Innovation Fund for Medical Science(2017-I2M-1-006); National Natural Science Foundation of China(81703309); Beijing Nova Program of Science and Technology(Z191100001119065)

More Information

Corresponding author: DAI Min, E-mail:daimin2002@hotmail.com

摘要

摘要: 恶性肿瘤已成为中国居民的主要死因之一。近些年来, 中国政府积极推进肿瘤预防和控制领域的研究工作, 取得了很大的进步。本文简要汇总中国在肿瘤流行病学领域的研究进展, 具体包括2019年的肿瘤负担、癌症危险因素及其干预、筛查和早期发现、癌症防治专项行动(2019-2022年)方案等方面, 以期为我国肿瘤防治工作的有效开展提供技术支撑和理论依据。
- 肿瘤 /
- 流行病学 /
- 队列研究
Abstract: Cancer is the leading cause of death in China. In recent years, Chinese government has advocated tremendous efforts in advancing research on cancer prevention and control, and has made great advancement. In this review, we briefly summarized the current research progress on cancer epidemiology in China, including the aspects of cancer burden, cancer-related risk factors and its intervention, screening and early detection, implementation plan of cancer prevention and control(2019-2022), in order to provide technical support and theoretical evidence in implementing effective cancer prevention and control in China in the future.
- Cancer /
- Epidemiology /
- Cohort study

HTML全文

参考文献(60)

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[2]	孙可欣, 郑荣寿, 张思维, 等. 2015年中国分地区恶性肿瘤发病和死亡分析[J].中国肿瘤, 2019, 28(1): 1-11. DOI:10.11735/j.issn.1004-0242.2019.01. A001. Sun KX, Zheng RS, Zhang SW, et al. Report of cancer incidence and mortality in different areas of China, 2015[J]. China Cancer, 2019, 28(1): 1-11. DOI: 10.11735/j.issn.1004-0242.2019.01.A001.
[3]	郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志, 2019, 41(1): 19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.005. Zheng RS, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015[J]. Chin J Oncol, 2019, 41(1): 19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.005.
[4]	Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567. DOI: 10.1016/S2214-109X(18)30127-X.
[5]	Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14(CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075. DOI: 10.1016/S0140-6736(17)33326-3.
[6]	Chen Z, Chen J, Collins R, et al. China Kadoorie biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up[J]. Int J Epidemiol, 2011, 40(6): 1652-1666. DOI: 10.1093/ije/dyr120.
[7]	Song C, Lv J, Liu Y, et al. Associations between hepatitis B virus infection and risk of all cancer types[J]. JAMA Netw Open, 2019, 2(6): e195718. DOI: 10.1001/jamanetworkopen.2019.5718.
[8]	Si J, Yu C, Guo Y, et al. Chronic hepatitis B virus infection and total and cause-specific mortality: a prospective cohort study of 0.5 million people[J]. BMJ Open, 2019, 9(4): e027696. DOI: 10.1136/bmjopen-2018-027696.
[9]	Wang L, Jin G, Yu C, et al. Cancer incidence in relation to body fatness among 0.5 million men and women: findings from the China Kadoorie biobank[J]. Int J Cancer, 2020, 146(4): 987-998. DOI: 10.1002/ijc.32394.
[10]	Li X, Yu C, Guo Y, et al. Association between tea consumption and risk of cancer: a prospective cohort study of 0.5 million Chinese adults[J]. Eur J Epidemiol, 2019, 34(8): 753-763. DOI: 10.1007/s10654-019-00530-5.
[11]	杨淞淳, 申泽薇, 余灿清, 等.中国成年人排便频率与结直肠癌发病风险的前瞻性关联分析[J].中华流行病学杂志, 2019, 40(4): 382-388. DOI: 10.3760/cma.j.issn.0254-6450.2019.04.003. Yang SC, Shen ZW, Yu CQ, et al. Association between the frequency of bowel movements and the risk of colorectal cancer in Chinese adults[J]. Chin J Epidemiol, 2019, 40(4): 382-388. DOI: 10.3760/cma.j.issn.0254-6450.2019.04.003.
[12]	Feng X, Wang G, Lyu Z, et al. The association between fasting blood glucose trajectory and cancer risk in Chinese population without diabetes[J]. Int J Cancer, 2020: epub of ahead. DOI: 10.1002/ijc.32858.
[13]	Lyu Z, Li N, Wang G, et al. Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males: A prospective cohort study[J]. Int J Cancer, 2019, 144(12): 2972-2984. DOI: 10.1002/ijc.32051.
[14]	王刚, 李霓, 冯小双, 等.炎性因子与乳腺癌发病风险的前瞻性队列研究[J].中华疾病控制杂志, 2019, 23(5): 517-521. DOI: 10.16462/j.cnki.zhjbkz.2019.05.005. Wang G, Li N, Feng XS, et al. The relationship between inflammatory factors and the risk of breast cancer in Kailuan cohort[J]. Chin J Dis Control Prev, 2019, 23(5): 517-521. DOI: 10.16462/j.cnki.zhjbkz.2019.05.005.
[15]	王刚, 魏锣沛, 李霓, 等.炎性因子水平与肺癌发病风险的前瞻性队列研究[J].中华肿瘤杂志, 2019, 41(8): 633-637. DOI: 10.3760/cma.j.issn.02533766.2019.08.014. Wang G, Wei L, Li N, et al. The relationship between inflammatory markers and the risk of lung cancer: a prospective cohort study[J]. Chin J Oncol, 2019, 41(8): 633-637. DOI: 10.3760/cma.j.issn.02533766.2019.08.014.
[16]	Li X, Chen H, Wang G, et al. Metabolic syndrome components and the risk of colorectal cancer: a population-based prospective study in Chinese men[J]. Front Oncol, 2019, 9: 1047. DOI: 10.3389/fonc.2019.01047.
[17]	Chen R, Ma S, Guan C, et al. The national cohort of esophageal cancer-prospective cohort study of esophageal cancer and precancerous lesions based on high-risk population in China(NCEC-HRP): study protocol[J]. BMJ Open, 2019, 9(4): e027360. DOI: 10.1136/bmjopen-2018-027360.
[18]	丁克峰.结直肠癌专病队列研究[J].中国科技成果, 2017, 18(24): 14. DOI: 10.3772/j.issn.1009-5659.2017.24.006. Ding KF. National cohort study of colorectal cancer[J]. Chinese Journal of Science and Technology Achievements, 2017, 18(24): 14. DOI: 10.3772/j.issn.1009-5659.2017.24.006.
[19]	Chen W, Xia C, Zheng R, et al. Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment[J]. Lancet Glob Health, 2019, 7(2): e257-e269. DOI: 10.1016/s2214-109x(18)30488-1.
[20]	Xia C, Hu S, Xu X, et al. Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study[J]. Lancet Public Health, 2019, 4(9): e462-e472. DOI: 10.1016/s2468-2667(19)30162-8.
[21]	Dai J, Lv J, Zhu M, et al. Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations[J]. Lancet Respir Med, 2019, 7(10): 881-891. DOI: 10.1016/s2213-2600(19)30144-4.
[22]	Lin GW, Xu C, Chen K, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations[J]. Lancet Oncol, 2020, 21(2): 306-316. DOI: 10.1016/s1470-2045(19)30799-5.
[23]	Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(11): 690-704. DOI: 10.1038/s41575-019-0209-8.
[24]	Parida S, Sharma D. The microbiome-estrogen connection and breast cancer risk[J]. Cells, 2019, 8(12): E1642. DOI: 10.3390/cells8121642.
[25]	Fan X, Alekseyenko AV, Wu J, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study[J]. Gut, 2018, 67(1): 120-127. DOI: 10.1136/gutjnl-2016-312580.
[26]	Wang Q, Rao Y, Guo X, et al. Oral microbiome in patients with oesophageal squamous cell carcinoma[J]. Sci Rep, 2019, 9(1): 19055. DOI: 10.1038/s41598-019-55667-w.
[27]	Li WQ, Zhang JY, Ma JL, et al. Effects of helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial[J]. BMJ, 2019, 366: l5016. DOI: 10.1136/bmj.l5016.
[28]	Wang SM, Abnet CC, Qiao YL. What have we learned from Linxian esophageal cancer etiological studies?[J]. Thorac Cancer, 2019, 10(5): 1036-1042. DOI: 10.1111/1759-7714.13058.
[29]	Qiao YL, Wu T, Li RC, et al. Efficacy, safety, and immunogenicity of an escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial[J]. J Natl Cancer Inst, 2020, 112(2): 145-153. DOI: 10.1093/jnci/djz074.
[30]	Wilson JM, Jungner YG. Principles and practice of mass screening for disease[J]. Bol Oficina Sanit Panam, 1968, 65(4): 281-393. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=5fb9cdf828d49ce0643ea2faea20900a
[31]	Goffin JR, Flanagan WM, Miller AB, et al. Cost-effectiveness of lung cancer screening in Canada[J]. JAMA Oncol, 2015, 1(6): 807-813. DOI: 10.1001/jamaoncol.2015.2472.
[32]	Lew JB, St John DJB, Xu XM, et al. Long-term evaluation of benefits, harms, and cost-effectiveness of the national bowel cancer screening program in Australia: a modelling study[J]. Lancet Public Health, 2017, 2(7): e331-e340. DOI: 10.1016/S2468-2667(17)30105-6.
[33]	Mandelblatt JS, Lawrence WF, Gaffikin L, et al. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries[J]. J Natl Cancer Inst, 2002, 94(19): 1469-1483. DOI: 10.1093/jnci/94.19.1469.
[34]	Pharoah PD, Sewell B, Fitzsimmons D, et al. Cost effectiveness of the NHS breast screening programme: life table model[J]. BMJ, 2013, 346: f2618. DOI: 10.1136/bmj.f2618.
[35]	de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume ct screening in a randomized trial[J]. N Engl J Med, 2020, 382(6): 503-513. DOI: 10.1056/NEJMoa1911793.
[36]	Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies[J]. BMJ, 2014, 348: g2467. DOI: 10.1136/bmj.g2467.
[37]	Kronborg O, Jorgensen OD, Fenger C, et al. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds[J]. Scand J Gastroenterol, 2004, 39(9): 846-851. DOI: 10.1080/00365520410003182.
[38]	Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer[J]. Br J Surg, 2008, 95(8): 1029-1036. DOI: 10.1002/bjs.6136.
[39]	Scholefield JH, Moss SM, Mangham CM, et al. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up[J]. Gut, 2012, 61(7): 1036-1040. DOI: 10.1136/gutjnl-2011-300774.
[40]	Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer[J]. N Engl J Med, 2013, 369(12): 1106-1114. DOI: 10.1056/NEJMoa1300720.
[41]	Nelson HD, Fu R, Cantor A, et al. Effectiveness of breast cancer screening: systematic review and Meta-analysis to update the 2009 U. S. preventive services task force recommendation[J]. Ann Intern Med, 2016, 164(4): 244-255. DOI: 10.7326/M15-0969.
[42]	Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India[J]. N Engl J Med, 2009, 360(14): 1385-1394. DOI: 10.1056/NEJMoa0808516.
[43]	Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies[J]. Sci Transl Med, 2014, 6(224): 224ra224. DOI: 10.1126/scitranslmed.3007094.
[44]	Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer[J]. Gut, 2014, 63(2): 317-325. DOI: 10.1136/gutjnl-2012-304149.
[45]	Choi KS, Kwak MS, Lee HY, et al. Screening for gastric cancer in Korea: population-based preferences for endoscopy versus upper gastrointestinal series[J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(5): 1390-1398. DOI: 10.1158/1055-9965.EPI-08-0940.
[46]	Hamashima C. Cancer screening guidelines and policy making: 15 years of experience in cancer screening guideline development in Japan[J]. Jpn J Clin Oncol, 2018, 48(3): 278-286. DOI: 10.1093/jjco/hyx190.
[47]	National Lung Screening Trial Research T, Church TR, Black WC, et al. Results of initial low-dose computed tomographic screening for lung cancer[J]. N Engl J Med, 2013, 368(21): 1980-1991. DOI: 10.1056/NEJMoa1209120.
[48]	Vale DB, Anttila A, Ponti A, et al. Invitation strategies and coverage in the population-based cancer screening programmes in the European Union[J]. Eur J Cancer Prev, 2019, 28(2): 131-140. DOI: 10.1097/CEJ.0000000000000426.
[49]	Parkin CJ, Bell SW, Mirbagheri N. Colorectal cancer screening in Australia: An update[J]. Aust J Gen Pract, 2018, 47(12): 859-863. DOI: 10.31128/AJGP-01-18-4472.
[50]	Zhou Q. MS16.02 NELCIN B3 screening program in China[J]. Journal of Thoracic Oncology, 2018, 13(10, Supplement): S272-S273. DOI: 10.1016/j.jtho.2018.08.154.
[51]	代敏, 石菊芳, 李霓.中国城市癌症早诊早治项目设计及预期目标[J].中华预防医学杂志, 2013, 47(2): 179-182. DOI: 10.3760/cma.j.issn.0253-9624.2013.02.018.
[52]	陈万青, 曹毛毛.加强癌症早诊早治, 实施健康中国战略[J].中国肿瘤, 2019, 28(9): 643. DOI:10.11735/j.issn.1004-0242.2019.09. A001 Chen WQ, Cao MM. Strengthening cancer early diagnosis and treatment, implementing the strategy of healthy China[J]. China Cancer, 2019, 28(9): 643. DOI: 10.11735/j.issn.1004-0242.2019.09.A001.
[53]	"两癌"筛查[J].中国卫生, 2019, (10): 54. Screening for breast cancer and cervical cancer[J]. Chinese Health, 2019, (10): 54.
[54]	Xiao HF, Yan SP, Chen YF, et al. Community-based upper gastrointestinal cancer screening in a randomized controlled trial: baseline results in a non-high-incidence area[J]. Cancer Prev Res(Phila), 2020, 13(3): 317-328. DOI: 10.1158/1940-6207.capr-19-0422.
[55]	Chen W, Zeng H, Chen R, et al. Evaluating efficacy of screening for upper gastrointestinal cancer in China: a study protocol for a randomized controlled trial[J]. Chin J Cancer Res, 2017, 29(4): 294-302. DOI: 10.21147/j.issn.1000-9604.2017.04.02.
[56]	Chen H, Li N, Ren J, et al. Participation and yield of a population-based colorectal cancer screening programme in China[J]. Gut, 2019, 68(8): 1450-1457. DOI: 10.1136/gutjnl-2018-317124.
[57]	He Z, Liu Z, Liu M, et al. Efficacy of endoscopic screening for esophageal cancer in China(ESECC): design and preliminary results of a population-based randomised controlled trial[J]. Gut, 2019, 68(2): 198-206. DOI: 10.1136/gutjnl-2017-315520.
[58]	Chen H, Li N, Shi J, et al. Comparative evaluation of novel screening strategies for colorectal cancer screening in China(TARGET-C): a study protocol for a multicentre randomised controlled trial[J]. BMJ Open, 2019, 9(4): e025935. DOI: 10.1136/bmjopen-2018-025935.
[59]	中华人民共和国国务院.健康中国行动(2019—2030年)[EB/OL]. (2019-7-15)[2020-3-02]. http://www.gov.cn/xinwen/2019-07/15/content_5409694.htm. StateCouncilofthePeople'sRepublicofChina.HealthyChinaaction(2019-2030)[EB/OL].(2019-07-15)[2020-03-02]. http://www.gov.cn/xinwen/2019-07/15/content_5409694.htm.
[60]	中华人民共和国国家卫生健康委员会.关于印发健康中国行动——癌症防治实施方案(2019-2022年)的通知[EB/OL]. (2019-09-23)[2020-03-02]. http://www.nhc.gov.cn/jkj/s5878/201909/2cb5dfb5d4f84f8881897e232b376b60.shtml. NationalHealthCommissionofthePeople'sRepublicofChina.NoticeonprintinganddistributinghealthChinaaction-cancerpreventionandcontrolimplementationplan(2019-2022)[EB/OL].(2019-9-23)[2020-3-02]. http://www.nhc.gov.cn/jkj/s5878/201909/2cb5dfb5d4f84f8881897e232b376b60.shtml.